Hexarelin · Research brief

Hexarelin Cost Per Month Budget — Research Pricing Guide

Real Peptides Research TeamEditorial

Updated April 15, 20269 min read

48 WORDS

Short answer

Key takeaways

Hexarelin cost per month budget ranges from $80 to $280 depending on dosing frequency, vial size, and supplier quality tier. Peptide cost alone accounts for 70–85% of total monthly spend.
A standard once-daily protocol at 200mcg consumes approximately 6mg monthly, requiring 1–2 vials depending on vial size purchased, with total monthly cost between $108 and $138 including supplies.
Research-grade hexarelin with per-vial HPLC verification costs 40–60% more than bulk peptides but eliminates the confounding variable of intra-batch purity variation that causes study failures.
Reconstituted hexarelin remains stable for 28 days when refrigerated at 2–8°C. Purchasing vial sizes larger than your 28-day consumption creates mandatory waste unless usage can be accelerated.
Dead volume in syringes accounts for 10–15% of total reconstituted solution across a typical monthly protocol. This hidden waste increases effective per-dose cost beyond simple vial-price calculations.
High-frequency protocols (twice or three times daily) consume more peptide monthly but also require proportionally more syringes and prep supplies, pushing total monthly budget 30–40% higher than once-daily protocols at equivalent total daily dose.

A 5mg vial of hexarelin priced at $60 looks deceptively affordable. Until you map actual monthly consumption against your research protocol and realize you're burning through 2–3 vials depending on dosing frequency. The real hexarelin cost per month budget isn't the vial price listed on a supplier's homepage. It's the sum of peptide cost, reconstitution supplies (bacteriostatic water, syringes, alcohol swabs), storage waste from temperature excursions, and the quality premium you pay for verified amino-acid sequencing instead of bulk-manufactured powder with unverified purity. Most protocols run 200–300mcg per administration at varying frequencies, which means monthly consumption ranges from 6mg to 18mg depending on whether you're dosing daily or multiple times per day.

Our team works with research institutions running hexarelin protocols across metabolic, cardiovascular, and neuroprotective studies. The gap between published per-vial pricing and actual monthly budget isn't margin. It's materials, waste mitigation, and the structural cost difference between verified research-grade synthesis and unverified commodity peptides.

What does a realistic hexarelin cost per month budget include. And why do most published prices understate actual research spending?

A realistic hexarelin cost per month budget for a standard research protocol ranges from $80 to $280 depending on dosage frequency, vial size purchased, and supplier quality tier. This includes peptide cost ($50–$180 for monthly consumption), bacteriostatic water ($8–$12 per 30mL bottle lasting 4–6 weeks), insulin syringes ($6–$10 per box of 100), and alcohol prep pads ($4 per box). High-frequency protocols (twice-daily dosing at 300mcg) consume 18mg monthly, requiring 3–4 vials at $60 each, pushing total spend to $240–$280. Single daily dosing at 200mcg consumes approximately 6mg monthly. Covered by one 5mg vial plus partial use of a second. Bringing monthly spend to $80–$120 including supplies.

The single largest variable in hexarelin cost per month budget is the quality tier of the peptide itself. Research-grade hexarelin synthesized with verified amino-acid sequencing through HPLC (high-performance liquid chromatography) and mass spectrometry confirmation costs 40–60% more than bulk-manufactured peptides sold without third-party purity verification. The markup isn't arbitrary. It reflects the cost of small-batch synthesis, individual vial testing, and chain-of-custody documentation required for reproducible research outcomes. At Real Peptides, every hexarelin vial undergoes HPLC verification before shipping, which is why our pricing sits above commodity suppliers but below the failures and retests that contaminated peptides trigger in controlled studies.

This article covers the line-item breakdown of monthly hexarelin research costs, the dosage-to-consumption calculations most protocols miss, supplier quality tiers and their impact on reproducibility, and the hidden costs (storage failure, reconstitution waste, protocol adjustments) that push actual spending 20–30% above initial estimates.

Dosage Protocol Determines Monthly Consumption

Hexarelin dosing in research settings typically ranges from 100mcg to 300mcg per administration, with frequency varying from once daily to three times daily depending on the biological endpoint being studied. A conservative once-daily protocol at 200mcg consumes 6mg per month (30 doses × 200mcg). A high-frequency protocol. Twice daily at 300mcg. Consumes 18mg monthly (60 doses × 300mcg). Most researchers underestimate monthly consumption because they calculate based on single-vial capacity (5mg or 10mg) without accounting for reconstitution waste, dead volume in syringes, and the fact that partial vials must be discarded after 28 days once mixed with bacteriostatic water.

The math: if your protocol calls for 200mcg twice daily, you're consuming 12mg monthly. A 10mg vial covers 20 days, meaning you'll need 1.5 vials per month. Since you can't buy half a vial, actual monthly spend requires two 10mg vials. If those vials cost $90 each, your peptide cost alone is $180. Before adding syringes, bacteriostatic water, or storage supplies. Researchers running pilot studies often purchase based on a single cycle without calculating the per-month cost across a 12- or 16-week protocol, which leads to budget shortfalls midway through the study when reordering is required.

Our experience shows that dosing frequency has more impact on monthly cost than dose size. A 100mcg dose administered three times daily (total 300mcg/day) consumes the same monthly peptide volume as a 300mcg dose given once daily. But the former requires three times the syringe and prep supply cost. High-frequency protocols also increase reconstitution frequency because smaller vials are depleted faster, creating more opportunities for contamination or storage error.

Vial Size and Per-Dose Cost Calculation

Hexarelin is most commonly available in 2mg, 5mg, and 10mg lyophilized vials. Per-milligram pricing decreases as vial size increases, but only if your protocol can fully consume the larger vial within the 28-day bacteriostatic water stability window. A 10mg vial priced at $100 ($10/mg) offers better unit economics than a 5mg vial at $60 ($12/mg). But only if you're dosing frequently enough to use all 10mg before the reconstituted solution degrades. If your protocol consumes 6mg monthly, purchasing a 10mg vial results in 4mg of waste unless you can accelerate usage or split the vial across concurrent studies.

Per-dose cost is calculated as (vial price ÷ total micrograms in vial) × dose in micrograms. Example: a 5mg vial at $60 contains 5,000mcg. At 200mcg per dose, that's 25 doses, or $2.40 per administration. A 10mg vial at $100 yields 50 doses at 200mcg, or $2.00 per dose. The 17% cost reduction per dose only materializes if all 50 doses are used before the 28-day clock expires. Single-investigator studies with infrequent dosing schedules often achieve lower total cost by purchasing smaller vials despite higher per-milligram pricing. The waste avoidance offsets the unit-price disadvantage.

Waste isn't limited to unused reconstituted peptide. Dead volume in syringes (the small amount of liquid trapped in the needle hub and plunger mechanism) accounts for approximately 0.05mL per draw. Across 60 administrations monthly, that's 3mL of solution. Equivalent to 10–15% of total reconstituted volume depending on concentration. Researchers using 1mL insulin syringes experience lower dead-volume loss than those using 0.5mL syringes, but the tradeoff is reduced dosing precision at very low volumes.

Supplier Quality Tiers and Cost Differential

Hexarelin cost per month budget varies substantially based on supplier quality tier. Three tiers dominate the research market: bulk/commodity suppliers ($8–$10 per mg, no purity verification), mid-tier suppliers with COA (certificate of analysis) availability ($12–$15 per mg, third-party tested batches), and research-grade suppliers with per-vial HPLC verification ($16–$20 per mg, full traceability and amino-acid sequencing confirmation). The price differential reflects manufacturing process, testing rigor, and failure rate in controlled studies.

Bulk suppliers source peptides from contract manufacturers without individual vial testing. Purity is batch-averaged, and contamination or degradation within a batch isn't detected until the peptide is used in-protocol. Mid-tier suppliers provide batch-level COAs but don't verify each vial, meaning intra-batch variability (one vial at 96% purity, another at 89%) isn't caught. Research-grade suppliers test every vial or use statistically valid sampling with full traceability, ensuring that the peptide you reconstitute matches the purity stated on the label. In reproducibility-critical studies. Dose-response curves, receptor binding assays, pharmacokinetic profiling. The 40–60% cost premium for verified peptides eliminates a confounding variable that bulk peptides introduce.

The hidden cost of low-quality hexarelin isn't the peptide price. It's the experiment failure. A contaminated or degraded vial that produces inconsistent results forces a protocol restart, consuming additional peptide, animal subjects or cell cultures, investigator time, and institutional overhead. One failed study due to peptide quality can cost 10–20× the savings from choosing a cheaper supplier. At Real Peptides, our small-batch synthesis model ensures that every hexarelin vial is HPLC-verified before shipping. The quality premium pays for itself in eliminated retests and reproducible dose-response data.

Comparison: Monthly Budget by Protocol Type

| Protocol Type | Dose per Administration | Frequency | Monthly Peptide Consumption | Vial Configuration | Peptide Cost | Supply Cost | Total Monthly Budget |
|—|—|—|—|—|—|—|
| Low-frequency research | 100mcg | Once daily | 3mg | 1 × 5mg vial | $60 | $15 | $75–$85 |
| Standard daily protocol | 200mcg | Once daily | 6mg | 1 × 5mg + partial 2nd vial | $90–$120 | $18 | $108–$138 |
| High-frequency protocol | 300mcg | Twice daily | 18mg | 2 × 10mg vials | $200 | $22 | $222–$242 |
| Dose-escalation study | Variable 100–300mcg | Daily | 9–12mg | 2 × 10mg vials | $180–$200 | $20 | $200–$220 |
| Professional Assessment | Low-frequency protocols achieve lowest per-month cost but extend study duration. High-frequency protocols front-load spending but compress timelines. Dose-escalation studies require vial flexibility. Purchasing mixed sizes (5mg + 10mg) reduces waste during lower-dose phases. |

What If: Hexarelin Budget Scenarios

What If My Protocol Requires Dosing More Frequently Than Expected?

Increase your monthly vial order proportionally and switch to larger vial sizes to reduce per-milligram cost. A protocol shift from once-daily to twice-daily dosing doubles monthly peptide consumption. If you were using one 5mg vial monthly, you'll now need two 5mg vials or one 10mg vial. The 10mg configuration offers better unit economics ($10/mg vs $12/mg) and reduces the number of reconstitution events, lowering contamination risk. Adjust your bacteriostatic water and syringe inventory accordingly. Twice-daily dosing requires double the prep supplies, not just double the peptide.

What If I'm Running a Dose-Escalation Study?

Purchase mixed vial sizes to match consumption at each dosing phase and avoid waste during lower-dose periods. Example: if your protocol starts at 100mcg daily for two weeks, then escalates to 200mcg daily for four weeks, then 300mcg daily for four weeks, your consumption profile is 1.4mg (weeks 1–2) + 5.6mg (weeks 3–6) + 8.4mg (weeks 7–10) = 15.4mg total. Purchasing three 5mg vials ($180) plus one 2mg vial ($30) closely matches consumption without forcing you to discard partial 10mg vials. Dose-escalation studies benefit from smaller vial increments even though per-milligram pricing is higher.

What If I Experience Storage Temperature Excursion?

Discard the affected vial immediately. Temperature excursions above 8°C cause irreversible peptide degradation that neither visual inspection nor home testing can detect. Lyophilized hexarelin can tolerate brief ambient temperature exposure (up to 25°C for 24–48 hours), but once reconstituted, the stability window collapses. If your refrigerator fails or a vial is left at room temperature for more than two hours, the safest assumption is total loss. This is why monthly hexarelin cost per month budget planning should include a 5–10% contingency for storage failures. One lost vial in a high-frequency protocol can derail a multi-week study if replacement inventory isn't on hand.

The Unflinching Truth About Hexarelin Research Budgets

Here's the honest answer: most published hexarelin pricing reflects single-vial cost, not the total monthly spend required to run a reproducible research protocol. Suppliers advertise per-vial pricing because it looks competitive. $60 for a 5mg vial positions them as affordable. What they don't show is the per-dose cost when you factor in reconstitution waste, dead volume, supply costs, and the quality premium required for purity verification. A $60 vial that produces inconsistent results isn't a bargain. It's a confounding variable that invalidates your data.

The structural cost difference between bulk peptides and research-grade hexarelin isn't profit margin. It's the cost of small-batch synthesis, individual vial HPLC testing, and chain-of-custody documentation. Bulk manufacturers amortize testing costs across large batches and don't verify individual vials, which is why intra-batch purity can vary by 5–10 percentage points. Research-grade suppliers like Real Peptides test every vial or use statistically valid sampling because reproducibility in controlled studies depends on knowing the exact purity of the peptide being administered. The 40–60% cost premium eliminates the single largest source of variability in dose-response experiments.

If your hexarelin cost per month budget is driving you toward the cheapest available supplier, ask whether you're optimizing for initial outlay or total cost of reproducible results. One failed study due to peptide contamination costs more than a year's worth of quality-verified peptides.

Planning a hexarelin research protocol requires accounting for peptide cost, reconstitution supplies, storage contingencies, and the quality tier that matches your reproducibility requirements. Monthly budgets range from $80 for low-frequency single-daily dosing to $280 for high-frequency protocols using research-grade peptides. The spread reflects dosage intensity and the structural cost of verified synthesis. If your study depends on reproducible dose-response data, the quality premium isn't optional. You can explore research-grade options including Hexarelin and see how verified amino-acid sequencing supports consistent experimental outcomes.

Questions

A standard once-daily protocol at 200mcg consumes approximately 6mg monthly, requiring 1–2 vials depending on vial size. Total monthly cost ranges from $108 to $138 including peptide ($90–$120), bacteriostatic water ($8–$12), insulin syringes ($6–$10), and alcohol prep pads ($4). High-frequency protocols dosing twice daily at 300mcg consume 18mg monthly, pushing total cost to $222–$242. The primary cost driver is peptide consumption — supplies account for only 15–20% of total monthly spend.

Larger vials offer better per-milligram pricing but only reduce monthly cost if your protocol can consume the full vial within 28 days of reconstitution. A 10mg vial at $100 ($10/mg) costs less per milligram than a 5mg vial at $60 ($12/mg), but if your protocol consumes only 6mg monthly, the unused 4mg becomes waste after the bacteriostatic water stability window expires. Low-frequency protocols often achieve lower total cost by purchasing smaller vials despite higher unit pricing — the waste avoidance offsets the per-milligram disadvantage.

Research-grade hexarelin with per-vial HPLC verification costs $16–$20 per milligram, while bulk peptides without individual vial testing cost $8–$10 per milligram — a 40–60% premium for verified purity. The price differential reflects small-batch synthesis, individual vial testing, and amino-acid sequencing confirmation that eliminates intra-batch variability. In reproducibility-critical studies, the quality premium pays for itself by preventing study failures caused by contaminated or degraded peptides — one failed experiment can cost 10–20× the savings from choosing a cheaper supplier.

Reconstituted hexarelin remains stable for 28 days when stored at 2–8°C in bacteriostatic water. After 28 days, peptide degradation accelerates regardless of storage conditions, reducing potency and introducing variability into dosing. Any temperature excursion above 8°C — even briefly — causes irreversible protein denaturation that neither appearance nor home potency testing can detect. Researchers should calculate monthly consumption before purchasing vial sizes and discard any reconstituted solution that exceeds the 28-day window or experiences temperature deviation.

A complete monthly hexarelin research protocol requires bacteriostatic water for reconstitution ($8–$12 per 30mL bottle, lasting 4–6 weeks), insulin syringes for administration ($6–$10 per box of 100), and alcohol prep pads ($4 per box of 200). High-frequency protocols dosing twice or three times daily consume supplies proportionally faster — twice-daily dosing requires double the syringe and prep pad inventory. Total monthly supply cost ranges from $15 to $25 depending on dosing frequency, representing 15–20% of total hexarelin cost per month budget.

Yes, but only if both studies run concurrently and can consume the full vial within the 28-day reconstitution stability window. Once mixed with bacteriostatic water, the entire reconstituted solution must be used or discarded within 28 days regardless of how it’s allocated. Splitting a 10mg vial between two studies dosing 100mcg daily each (total 200mcg/day combined) consumes 6mg monthly — leaving 4mg as waste unless dosing frequency increases. The logistics of maintaining sterile multi-draw technique across two protocols increases contamination risk, so vial splitting is only advisable when the combined consumption closely matches vial size.

Per-dose cost is calculated as (vial price ÷ total micrograms) × dose size. A 5mg vial at $60 contains 5,000mcg — at 200mcg per dose, that’s $2.40 per administration. A 10mg vial at $100 yields $2.00 per dose at the same 200mcg dosing. The 17% per-dose savings only materializes if all doses are used within the reconstitution stability window. Low-frequency protocols often achieve better total economics with smaller vials despite higher per-dose cost because waste avoidance offsets unit-price disadvantage.

Research-grade suppliers perform per-vial HPLC verification or statistically valid sampling to confirm amino-acid sequencing and purity before shipping, while bulk suppliers batch-test without verifying individual vials. The cost differential reflects small-batch synthesis, individual vial testing, chain-of-custody documentation, and the elimination of intra-batch variability that bulk manufacturing introduces. In dose-response studies and receptor binding assays, peptide purity is a confounding variable — spending 40–60% more for verified peptides eliminates the largest source of experimental inconsistency and prevents study failures that cost far more than the quality premium.

Dosing frequency determines both peptide consumption and supply cost. A once-daily protocol at 200mcg consumes 6mg monthly; twice-daily at the same dose consumes 12mg. Beyond doubled peptide cost, high-frequency protocols require proportionally more syringes and prep supplies — twice-daily dosing needs double the syringe inventory. A shift from once-daily to twice-daily dosing typically increases total monthly budget by 80–100% when peptide and supply costs are combined. Low-frequency protocols minimize monthly cost but extend study duration, while high-frequency protocols front-load spending to compress timelines.

Dead volume in syringes and reconstitution waste — factors most researchers don’t account for when calculating monthly cost. Dead volume (liquid trapped in the needle hub and plunger) accounts for approximately 0.05mL per draw; across 60 monthly administrations, that’s 3mL of solution or 10–15% of total reconstituted volume depending on concentration. Reconstitution waste occurs when vials are discarded after 28 days with peptide remaining, or when temperature excursions force early disposal. Combined, these hidden costs increase effective monthly spend by 15–25% above simple vial-price calculations.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA